Blueprint Medicines is a developer of selective kinase inhibitors targeting genomically defined cancers. Its two lead product candidates are BLU-285, a selective inhibitor of KIT Exon 17 mutants, and BLU-554, a selective FGFR4 inhibitor. The company plans to initiate clinical trials in 2015 for both candidates, including two studies for BLU-285—one for systemic mastocytosis and another for genomically defined subsets of gastrointestinal stromal tumors (GIST)—and a study of BLU-554 for hepatocellular carcinoma with aberrant FGFR4 pathway activation. Blueprint also focuses on the continued development of its kinase discovery platform and broader pipeline. Financially, the company completed a $50M Series C financing to advance its lead candidates and support platform and pipeline development. Blueprint Medicines develops highly selective kinase inhibitors targeted at genomically defined subsets of cancer patients using a platform that combines genomics with a novel kinase inhibitor library. Its lead programs include selective inhibitors of the KIT D816V mutation for systemic mastocytosis and a genomically defined subset of gastrointestinal stromal tumors (GIST). The pipeline also includes isoform‑selective FGFR4 inhibitors for hepatocellular carcinoma with FGF19 amplification and other tumors. Blueprint planned to initiate clinical trials for these programs in 2015 and intends to develop candidates as single agents in late‑stage and resistant populations and in combinations in earlier lines. The company emphasizes rapid development toward clinical proof‑of‑concept in well‑defined patient populations. Blueprint was founded in 2011 and is privately held, initially financed by Third Rock Ventures and Fidelity Biosciences. Blueprint Medicines develops personalized, highly‑selective cancer therapies that target driver molecular aberrations and emerging resistance mechanisms. The company leverages a proprietary chemical compound library and its Insights-to-Validation™ Platform to discover and advance novel therapeutic compounds and combination therapies. Founded in 2011 and based in Cambridge, Mass., Blueprint was co-founded by Nicholas Lydon, Brian Druker, Chris Varma, David Armistead and Third Rock Ventures. Its management, board and founding advisors include industry veterans and academic leaders such as Drs. Lydon and Druker, Mark Levin, Alexis Borisy and advisor Scott Lowe. The company announced a $40 million Series A financing led by Third Rock Ventures, and said proceeds will be used to develop new cancer therapies. Blueprint aims to translate growing cancer genomic data into selective, patient‑defined treatments to improve outcomes and make cancer more manageable.

Total raised

$115M

Funding rounds

3

Latest round

Series C

Latest activity

Nov 2014